Has Amber Flaherty, MD received payments from drug or device companies?

Yes. Drug and device makers reported $398,806 in general payments to Amber Flaherty, MD across 1,358 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amber Flaherty, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amber Flaherty, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amber Flaherty, MD

Medical Oncology · Phoenix, AZNPI 1093008336

Payments from drug & device makers

$398,806in general payments, 2019–2025

Across 1,358 payments — averaging $293.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$171K
Janssen Research & Development, LLC$122K
E.r. Squibb & Sons, L.L.C.$47K
Seagen Inc.$18K
Global Blood Therapeutics, Inc.$12K
Merck$6K
plus $22K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead(2 entities)	19	$171,053
Janssen Research & Development, LLC	389	$121,990
E.r. Squibb & Sons, L.L.C.	63	$47,021
Seagen Inc.	32	$18,180
Global Blood Therapeutics, Inc.	14	$11,791
Merck	72	$6,049
Pfizer	76	$5,405
Clovis Oncology, Inc.	2	$2,121
Novartis	58	$1,526
AstraZeneca(2 entities)	51	$1,088
Johnson & Johnson	52	$1,000
Daiichi Sankyo Inc.	49	$971
Bristol Myers Squibb	55	$908
Amgen	34	$743
Exelixis Inc.	8	$578
Sanofi	27	$569
Lilly USA, LLC	21	$482
Genentech USA, Inc.	24	$470
Eisai Inc.	25	$454
Incyte Corporation	18	$399
AbbVie	17	$337
Bayer	16	$315
Astellas Pharma US Inc	13	$266
Tersera Therapeutics LLC	9	$257
Blueprint Medicines Corporation	11	$255
Takeda Pharmaceuticals U.S.A., Inc.	10	$231
Ipsen Biopharmaceuticals, Inc	11	$216
EMD Serono, Inc.	12	$209
GSK	10	$208
Adaptive Biotechnologies Corporation	7	$195
Array Biopharma Inc	10	$184
Sobi, Inc	10	$165
Stemline Therapeutics Inc.	7	$162
Genmab U.S., Inc.	5	$154
Pharmacyclics LLC, An Abbvie Company	7	$144
Sumitomo Pharma America, Inc.	2	$143
Springworks Therapeutics, Inc.	5	$133
Karyopharm Therapeutics Inc.	6	$131
Puma Biotechnology, Inc.	6	$129
Immunomedics, Inc.	1	$125
Beigene USA, Inc.	6	$123
Sun Pharmaceutical Industries Inc.	6	$122
Regeneron Healthcare Solutions, Inc.	5	$113
Pharmacosmos Therapeutics Inc.	5	$105
Rigel Pharmaceuticals, Inc.	5	$104
Jazz Pharmaceuticals Inc.	3	$90
Sanofi-aventis U.S. LLC	1	$89
Boehringer Ingelheim	5	$81
Coherus Oncology, Inc.	3	$77
ADC Therapeutics America, Inc.	3	$75
Dendreon Pharmaceuticals LLC	3	$75
AVEO Pharmaceuticals, Inc.	3	$70
Servier Pharmaceuticals LLC	3	$69
Taiho Oncology, Inc.	3	$68
Kyowa Kirin, Inc.	3	$59
Morphosys, US Inc.	3	$58
Progenics Pharmaceuticals, Inc.	2	$49
Mirati Therapeutics, Inc.	2	$45
G1 Therapeutics, Inc.	2	$42
Alnylam Pharmaceuticals Inc.	2	$35

How this compares

$398,806 in reported general payments places this provider in the 80th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona →

Medicare billing

Part B allowed, 2024

$1,682,943

Medicare patients

355

Services billed

75,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Phoenix

Jason SalganickPhoenix$1.6M
Mital PatelPhoenix$484K
Albert WendtPhoenix$393K
Vamsee TorriPhoenix$268K
Debra WongPhoenix$184K
Amir AzadiPhoenix$151K
Harshita ParipatiPhoenix$151K
Waqas ArslanPhoenix$39K
Angela SaverimuthuPhoenix$35K
Haider ZafarPhoenix$7K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →